FDA Trending News

FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List

Jun 1, 2026

The U.S. Food and Drug Administration today announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.

The 503B bulks list identifies bulk drug substances that outsourcing facilities may use in compounding under the conditions of section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act). In most cases, outsourcing facilities cannot compound drugs using bulk drug substances unless the substance appears on the 503B bulks list, or the compounded drug is on the FDA’s drug shortage list at the time of compounding, distribution, and dispensing.

After evaluating the nominations for these three substances, the FDA did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances.

“When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need,” said FDA Commissioner Marty Makary, M.D., M.P.H. “This action reflects our responsibility to protect patients and preserve the integrity of the drug approval process while continuing to provide a transparent, science-based pathway for public input.”

The FDA carefully reviewed the nominations it received and did not identify sufficient evidence to include semaglutide, tirzepatide and liraglutide on the 503B bulks list. A determination of clinical need is based on patient safety and medical necessity under the law.

The FDA is now inviting interested parties to submit comments electronically through the docket by June 29, 2026. The agency will consider submitted comments before making a final determination.

Source:

U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List [Internet]. Silver Spring (MD): FDA; 2026 Apr 30 [cited 2026 May 5]. Available from: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list

Reported by

Reviewed by

You May Also Like

Could a New Discovery Prevent Muscle Loss and Weakness as We Age?

Could a New Discovery Prevent Muscle Loss and Weakness as We Age?

,

Muscle weakness is one of the biggest challenges of aging. As people get older, they naturally lose muscle strength and muscle mass, a condition known as sarcopenia. This can make everyday activities like climbing stairs, carrying groceries, or getting up from a chair much more difficult. While exercise and good nutrition remain the best ways to slow muscle loss, researchers are searching for new treatments that target the underlying causes of age-related muscle weakness.

Could Glucosamine Supplements Worsen Alzheimer’s Disease? Here’s What Researchers Found

Could Glucosamine Supplements Worsen Alzheimer’s Disease? Here’s What Researchers Found

, ,

Many people take glucosamine supplements every day to help support their joints. It has been used for years and is one of the most popular supplements for osteoarthritis. However, a new study is raising questions about whether glucosamine could affect brain health in people with Alzheimer’s disease or mild cognitive impairment.

The Facts on Tampons and Tampon Safety

The Facts on Tampons and Tampon Safety

,

Tampons are absorbent products that you insert into your vagina to soak up menstrual flow during your period. Tampons come in different absorbency levels — like light, regular, and super — so you can pick the right one for your flow. Some have a plastic or cardboard applicator to help with insertion, and others are inserted with your finger.